which may be linked to the conjugation technology used in the drug and features as a black box warning on the product's label. The risk is said to be behind the somewhat slow take-up of Enhertu ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical ...

In the study, Enhertu was given to patients with HER2-low ... which features as a black box warning on the product's label. DESTINY-Breast03 and 04 as well as data in HER2-positive non-small ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...